September 19, 2025Open Access

Exploiting TGF-β-mediated Stromal Programming in Homologous Recombination-Deficient Pancreatic Cancer

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Research demonstrates TGF-β signaling promotes cancer aggressiveness in PDAC, indicating targeting could improve therapies.

ATM deficiency leads to myofibroblastic differentiation in CAFs, promoting cancer aggressiveness and chemoresistance.
Pharmacological TGF-β inhibition reverses myCAF differentiation and sensitizes tumors to chemotherapy.
Single-nucleus multiomics and genetically engineered mouse models reveal TGF-β's role in shaping the tumor microenvironment.
Targeting both intrinsic and extrinsic vulnerabilities presents a promising strategy for precision oncology.

Roger et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark